Scarlet, a London-founded certification body for AI and software medical devices, said on 12 October 2026 that it has raised $50m in Series B funding led by Headline. In its own announcement, the company says the money will help it build “a truly global AI certification body”.
The post names existing investors Kindred Capital, Creandum, Atomico and Entrepreneurs First (EF), and new investor Notion Capital. It says the round will let Scarlet certify AI in all its forms, grow its team of experts and increase its footprint in the US and APAC.
Scarlet’s post says that in the past year it has seen demand for AI medical device certification “skyrocket”. It says its customers have cut a year or more from their certification timelines for new AI-enabled devices, and shortened product-update cycles from months to weeks. Those are the company’s own figures for its customers.
Tech.eu, which reported the round on 12 October, describes the gap Scarlet is aiming at: a company can train an AI diagnostic model in weeks and then wait 12 to 18 months for an assessment by experts, with another six to eight months of delay for approval of a minor update.
According to Tech.eu, customers upload technical documentation to Scarlet’s AI-enabled platform, qualified reviewers assess it against the relevant regulations, and the reviewers issue the certification decision. Customers pay a subscription that covers ongoing surveillance, annual audits and product changes, the article says.
The investors Scarlet names in its 12 October 2026 post: Headline (lead), new investor Notion Capital, and existing investors Atomico, Creandum, Kindred Capital and Entrepreneurs First. Scarlet’s post gives no valuation.
Business Pill · LEAD TIME
A one-minute explainer of lead time: the wait between deciding to do something and it being done. It teaches the general idea only and says nothing about any person or organisation in this story.
The key insight: As we read it, Scarlet is selling time. The company’s own claim is that its customers have cut a year or more from certification timelines for new AI-enabled devices, and that product-update cycles fell from months to weeks.
Who Is Behind It
Tech.eu says James Dewar and Jamie Cox founded Scarlet in London in 2021 after building AI medical devices at Babylon Health, and that the company spent its first three years working with regulators to obtain designation before issuing any certificates.
The article lists customers including Flo Health, DeepHealth, NHS England, Skin Analytics, Heidi Health and Tandem. It quotes Dewar: “For every day that safe and effective medical technology is not available, someone’s life takes a different course. Scarlet exists to solve this problem.”
Nancy Xiao McLaughlin, a partner at Headline, is quoted as saying: “Scarlet helps regulation work with and for, not against, innovation.”
The Designations
Tech.eu says Scarlet is one of roughly 52 organisations designated under the EU Medical Device Regulation, and, according to the company, the only one that specialises in software and AI. It says Scarlet holds designations from the EU, the UK’s MHRA and the US FDA, where it is recognised as a Third Party Review Organisation.
We checked the UK part on GOV.UK. On 31 January 2024 the MHRA announced that Scarlet NB UK had been designated as a UK Approved Body “with a focus on assessing and certifying software and AI as a medical device (AI/SaMD)”. The government’s list of UK approved bodies, updated on 17 July 2026, includes a scope document for Scarlet NB UK Ltd.
The Structural Read
As we read it, the bottleneck Tech.eu describes is not building the model but getting it cleared: an AI diagnostic model can be trained in weeks, the article says, then wait 12 to 18 months for an assessment.
As we read it, the subscription Tech.eu describes, covering ongoing surveillance, annual audits and product changes, makes certification a continuing relationship rather than a one-off approval.
Scarlet’s UK designation is on the government’s register: the MHRA said on 31 January 2024 that Scarlet NB UK was designated with a focus on software and AI as a medical device.
James Dewar, Scarlet’s co-founder and CEO, as quoted by Tech.eu, 12 October 2026
“For every day that safe and effective medical technology is not available, someoneโs life takes a different course. Scarlet exists to solve this problem.”
Three Implications
AI MEDICAL DEVICE MAKERS Scarlet says the round will let it certify AI in all its forms and grow its team of experts; Tech.eu says customers include Flo Health, DeepHealth and NHS England.
OTHER CERTIFICATION BODIES Tech.eu says roughly 52 organisations are designated under the EU Medical Device Regulation and, according to the company, Scarlet is the only one that specialises in software and AI.
INVESTORS Scarlet’s post names Headline as lead, Notion Capital as a new investor, and Kindred Capital, Creandum, Atomico and Entrepreneurs First as existing investors.
The framework puts it this way: “They are not the same curve, and the gap between them — what the platform makes possible versus what the product surfaces — has a name.”
As we read it, in AI medical devices part of that gap is regulatory: what a model can do on day one versus what patients can use after certification. Scarlet is raising to narrow that part.
The designations Tech.eu lists for Scarlet. Highlighted: the UK Approved Body status, which we checked on GOV.UK (MHRA, 31 January 2024, with an AI/SaMD focus). We did not check the EU and FDA registers ourselves.
What Is Not Established
Scarlet’s post gives no valuation, no revenue and no count of certificates issued. The customer time savings are the company’s own figures. We did not check Scarlet’s EU notified-body entry or its FDA recognition against the official EU and FDA lists; those statements are attributed to the company and Tech.eu. The figure of about 52 bodies under the EU regulation is Tech.eu’s.
Business Engineer Framework
The Product Overhang Doctrine
A Business Engineer framework on the gap between what a technology can do and what users can actually do with it.
Scarlet says it has raised $50m, led by Headline, to grow a certification body built for AI medical devices, with expansion in the US and Asia-Pacific. Its UK approved-body designation, focused on software and AI, is on the government’s register. Its pitch is speed: the company says customers cut a year or more from certification timelines.
A note on sourcing. On 12 October 2026 we read Scarlet’s own announcement of the round in full, and checked its UK designation on GOV.UK: the MHRA’s 31 January 2024 announcement and the government’s list of UK approved bodies. Details on the founders, customers, delays and the EU and US designations come from Tech.eu’s 12 October report, credited where used; we did not check the EU and FDA registers ourselves. The customer time savings are the company’s own figures. Nothing here is investment advice.
Gennaro Cuofano is a CRO and tech executive who has worked in AI since late 2015, starting with bringing NLP, natural-language generation, voice and chatbot products to the marketing industry. His background is in law and finance: he holds a Master's degree in Law and an International MBA with an emphasis on corporate finance (LUISS Business School and the University of San Diego, 2012), and worked as a financial analyst at a real-estate investment firm in San Diego and as an assistant controller. His work focuses on business model strategy, business engineering and, more broadly, structural analysis: how companies make money, read from their own filings. He created FourWeekMBA and leads research there and at The Business Engineer, his newsletter on AI and business strategy, with over 95,000 subscribers and more than 1,000 published analyses. His writing has also appeared on Entrepreneur, HackerNoon and Search Engine People. Find him on LinkedIn and Substack. See how we source.
Scroll to Top
Discover more from FourWeekMBA
Subscribe now to keep reading and get access to the full archive.
